



RESULTS **MARKETS MUTUAL FUNDS IPO** COMMODITIES **WEALTH PORTFOLIO MESSAGES MY TV** CNBC-TV18 HOME BUSINESS GENERAL NEWS FUND NEWS PERSONAL FINANCE CORPORATE STRATEGY LIFESTYLE **POLITICS** LEGAL MARKET TRENDS STOCKS

Indian bio-pharma R&D spending could grow to \$25 bn by 2025

Published on Fri, Jun 24, 2011 at 10:00 | Source : PTI Updated at Fri. Jun 24, 2011 at 15:08

10 Stocks to Hold Forever www StreetAuthority com Buy them, forget about them, and never sell them.

Like this story, share it with millions of investors on M3







0

tweets

3

in Share

tumblr

Print

Email



India's bio-pharma sector may see a surge in R&D spending to about USD 25 billion in the next 15 years, according to a Boston Consulting Group report that said favourable policies need to be implemented to attract investment and enhance innovation in the field.

The total amount that is currently being spent on innovative discovery programmes and development in the bio-pharma sector in India is about USD 2

billion.

This amount can grow to USD 25 billion by 2025 if concerted efforts are made by various stakeholders like the government, academia and industry on developing R&D and innovation in the bio-pharma field.

The investment is expected to come from multinationals, Indian industry and funding organisations ploughing money into discovery and innovation.

"The Indian government needs to implement favourable policies that enhance innovation and drive collaborations, besides addressing issues in critical building blocks like talent and infrastructure," BCG said in its position paper, titled, 'Life Sciences R&D: Changing the innovation Equation in India'.

The paper was presented here today at the US-India Bio-Pharma summit organised by the USA-India Chamber of Commerce.

"While the government has taken concrete measures over the last decade to establish an innovation ecosystem, Indian stakeholders have to accelerate their capability to enable global bio-pharma to develop an India innovation strategy," the report added.

The paper outlined recommendations for Indian service providers, academia and the pharma sector that will help boost spending in the country's bio-pharma field over the next few years.

It said Indian service providers should develop a differentiated value proposition to emerge as attractive innovation partners for global bio-pharma.

It suggested that the Indian pharma sector transform its business model from an integrated to a

GET QUOTE

GO

News

MOST POPULAR **TOP NEWS**

- Lucky 13: Best investments of 2011
- 11 stocks that have crashed anywhere between 16-60% in 5 months
- In pics: Market rejuvenates, but experts stay cautious
- State of the economy: How does India Inc see it?
- Global rally takes Sensex near 1-month high; Nifty reclaims 5100

network approach to develop 'nichebusters', while the academia should drive commercialisation in institutes by encouraging collaborations and entrepreneurship.

If the action programme laid out for the various stakeholders is realised, the amount of money that would subsequently be spent in the Indian bio-pharma field could be about USD 25 billion by 2025, BCG partner Bart Janssens said.

India still accounts for only about 1% of the overseas R&D investments made by US bio-pharma companies -- similar to China's share (also about 1%), but much smaller than the share of Eastern Europe (about 8%) and Latin America (about 4%).

"We feel that India's research sector still has tremendous opportunities for growth, particularly with bio-pharma companies struggling to resolve the crisis in R&D productivity," Janssens added.

India is attracting more investment in bio-pharma R&D, but still lacks recognition as an innovation partner, the report said.

Over the past 10 years, India has made a concerted effort to capitalise on the globalisation of R&D investments.

US bio-pharma companies spent 24% of their R&D budgets in foreign countries in 2009, up from 17% in 2002.

Over the same period, India's share of these foreign expenditures increased ten-fold to about USD 500 million.

Tags: India's bio-pharma sector, R&D spending, Boston Consulting Group

FIRSTPOST. NEWS BREAKS



Pre-payment penalty: RBI proposes, will banks size up?

07 Sep 09:16 am IST

Latest on



Home Minister Detailed Forensic Report To Be Available Tomorrow

Watch Now

The latest earning numbers FIRST on CNBC-TV18